ZA200200597B - Combination theraphy. - Google Patents

Combination theraphy.

Info

Publication number
ZA200200597B
ZA200200597B ZA200200597A ZA200200597A ZA200200597B ZA 200200597 B ZA200200597 B ZA 200200597B ZA 200200597 A ZA200200597 A ZA 200200597A ZA 200200597 A ZA200200597 A ZA 200200597A ZA 200200597 B ZA200200597 B ZA 200200597B
Authority
ZA
South Africa
Prior art keywords
theraphy
combination
combination theraphy
Prior art date
Application number
ZA200200597A
Other languages
English (en)
Inventor
Tracey Wayne Ross
Hill Roger James
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200200597B publication Critical patent/ZA200200597B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200200597A 2001-01-25 2002-01-23 Combination theraphy. ZA200200597B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26417301P 2001-01-25 2001-01-25

Publications (1)

Publication Number Publication Date
ZA200200597B true ZA200200597B (en) 2003-07-23

Family

ID=23004913

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200200597A ZA200200597B (en) 2001-01-25 2002-01-23 Combination theraphy.

Country Status (12)

Country Link
EP (1) EP1226830A3 (xx)
JP (1) JP2002275096A (xx)
KR (1) KR20020062842A (xx)
CN (1) CN1370531A (xx)
AU (1) AU1197802A (xx)
CA (1) CA2369212A1 (xx)
HK (1) HK1048265A1 (xx)
HU (1) HUP0200253A3 (xx)
IL (1) IL147696A0 (xx)
NZ (1) NZ516792A (xx)
PL (1) PL351865A1 (xx)
ZA (1) ZA200200597B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219421A1 (en) * 2002-05-02 2003-11-17 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors
US7109169B2 (en) * 2002-06-28 2006-09-19 Hobai Ion A Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange
CN101132802A (zh) * 2004-03-24 2008-02-27 法斯根有限责任公司 通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD87029A (xx) *
DK0589336T3 (da) * 1992-09-22 1997-06-16 Hoechst Ag Benzylguanidiner, fremgangsmåde til deres fremstilling samt deres anvendelse som antiarytmetika
US5248673A (en) * 1992-12-23 1993-09-28 Bristol-Myers Squibb Co. Bisamidine derivatives as thrombin inhibitors
WO1995023809A1 (en) * 1994-03-04 1995-09-08 Eli Lilly And Company Antithrombotic agents
DE4430861A1 (de) * 1994-08-31 1996-03-07 Merck Patent Gmbh Heterocyclyl-benzoylguanidine
CA2160600A1 (en) * 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
US5559150A (en) * 1995-06-06 1996-09-24 3-Dimensional Pharmaceuticals, Inc. N,N-disulfonylated aminobenzene carboxlic acids and the use thereof as thrombin inhibitors
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
EP0855392A3 (de) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6258829B1 (en) * 1997-03-06 2001-07-10 Toa Eiyo Ltd. Cycloalka[b]pyridine-3-carbonylguanidine derivatives, process for producing the same, and drugs containing the same
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
SI1056729T1 (en) * 1998-02-27 2005-04-30 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl)guanidine derivatives for the treatment of ischemia
EP0950418A2 (en) * 1998-04-14 1999-10-20 Takeda Chemical Industries, Ltd. Composition for preventing or treating ischemic disease
TR200102810T2 (tr) * 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler

Also Published As

Publication number Publication date
AU1197802A (en) 2002-08-01
EP1226830A2 (en) 2002-07-31
CA2369212A1 (en) 2002-07-25
JP2002275096A (ja) 2002-09-25
IL147696A0 (en) 2002-08-14
NZ516792A (en) 2003-09-26
EP1226830A3 (en) 2003-07-09
PL351865A1 (en) 2002-07-29
HUP0200253A3 (en) 2003-04-28
HU0200253D0 (en) 2002-03-28
KR20020062842A (ko) 2002-07-31
HK1048265A1 (zh) 2003-03-28
CN1370531A (zh) 2002-09-25
HUP0200253A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
ZA200208561B (en) Hydraulischer druckverstarker.
ZA200401015B (en) Compounds effecting glucokinase.
MXPA03007166A (es) Pirido-pirimidinas 6-sustituidas.
MXPA03005081A (es) Elevador.
MXPA03009229A (es) Microcapsulas.
HK1051639A1 (en) Buckle.
MXPA01009037A (es) I-bet.
MXPA03009583A (es) Ftalazinonas novedosas.
MXPA03006261A (es) Compuestos terapeuticos de cromano.
EG23387A (en) Spirocyclic 3-phenyl-3-substituted 4-ketolactams and-lactones.
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03008164A (es) Agentes anti-epileptogenos.
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
MXPA03008394A (es) Derivados de biuretano.
HK1059781A1 (en) New phenylpiperazines.
MXPA03007888A (es) Compuestos para tratamiento y prevencion de ulcera gastrica inducida por medicamentos.
ZA200200597B (en) Combination theraphy.
ZA200204985B (en) Activated rec-D-hydantoinases.
GB0124935D0 (en) The safetycom
GB0112267D0 (en) The pagekeeper
AP2001000098S (en) Marimbira.
MXPA01005709A (es) Panel-cimbra.
MXPA01005710A (es) Losa-cimbra.
GB0118494D0 (en) P.c.o.
GB0116210D0 (en) P.c.o